Spinal muscular atrophy (SMA) is a progressive neuromuscular disease in which long-term management increasingly extends into adolescence and adulthood. As survival improves, clinicians are frequently navigating how best to preserve motor function, functional independence, and quality of life over time. In this context, treatment durability and longitudinal stability have become central considerations in real-world care.
In clinical practice, some patients and caregivers report cyclical changes in strength, endurance, or fatigue between treatment intervals. Interpreting these changes can be challenging. Perceived variability may reflect multiple factors, including underlying disease course, growth-related biomechanical changes, scoliosis progression, reduced access to rehabilitation services, intercurrent illness, or changes in activity levels—rather than treatment effect alone.
When clinicians suspect interval-related variability, confirming the pattern and evaluating modifiable contributors—such as sleep, activity demands, respiratory status, or rehabilitation disruptions—may help clarify whether observed changes reflect treatment timing, disease progression, or a combination of factors. Patient-reported outcomes, functional assessments, and longitudinal trend tracking can provide additional context when evaluating stability over time.
Treatment decisions for teens and adults living with SMA often involve balancing functional goals, treatment logistics, administration considerations, and evolving life circumstances. As patients age, factors such as visit burden, procedure tolerance, access to care, and long-term planning may influence decisions around treatment continuation, restarts, or adjustments. Importantly, expectations around reversibility must be carefully managed, as stabilization or slowed decline may represent meaningful benefit in a progressive disease.
In your experience, what clinical or patient-reported signs most influence how you assess long-term treatment durability in adolescents or adults with SMA? How do logistical considerations, functional goals, and patient preferences factor into decisions around treatment continuation, restarts, or changes over time?
Share
-
Paola Sandroni3dI try to monitor specific actions, ADLs that the patient can use to monitor their progress. So each patient is their own benchmark -
Belinda H3wtreatments are going to be desirable and used long term if they are able to maintain functional independence for the patient with limited undesirable side effects
-
Anjaneyulu Alapati4wactivities of daily living, functional status, ambulation
-
Leon Ronen1moFocusing on abilities and limitations with goal of improving function and independence and strengthening mental as well as physical issues
-
Kathryn Welch1moI have several SMA type 1 patients so it's a new world for both of us. Our goals are to have them be as independent as possible so if we see regression, we consider other treatment options to gain those skills back
-
Joel Washinsky1moTrying to achieve realistic independence for the patient as possible. Give the patient much support and realistic hope.
-
ANDREW ROGOVE1moAs SMA is progressive it is important to be realistic with goals and expectations, while maintaining optimism. It is also important to focus on my patients' abilities, rather than their disabilities. Clinical course will help dictate treatments and goals over time
-
SACHINKUMAR PANCHAL1moTo help patients live good quality and healthy life. Good caregivers and supportive staff.
-
Jack Su1moSMA is not my area of expertise, but I would venture to guess that functional independence would be at the top of the list; other secondary goals would be subjective report of quality of life, parental questionnaires, and objective parameters from the treatment team
-
Crystal Worsena1moI would say the most important thing is assessing there activities of daily living whether that is an informal assessment or through a questionnaire because the goal is to keep them as functional and independent as possible over time. In our community patient's are more rule so do have to travel for higher level of treatment that definitely plays into our treatment goals especially as things progress over time. And ultimately patients have the final say regarding their preference and what they want for their life when discussing treatment
-
Rahat Sheikh1moFunctional independence is very important and assessment of ADLs is of utmost importance, this will enable patients to live healthy and indepenently
-
Terry Cheung1moAssessing the patient's ability to perform ADLS on their own w/o any assistance or help from others is imperative and essential to every appointment. Take into consideration the goals of the patient and what their expectations are when it comes to ADLs and quality of life.
-
Liang Lu1moFunctional independence to perform ADLs without assistance is most impactful and consequential. Clinical Decisions regarding the initiation, continuation, and modification of SMA treatments—including Spinraza, Zolgensma and Evrysdi—are thoroughly individualized. Treatment strategies are generally tailored to the patient’s age, disease severity, SMN2 copy number, and treatment goals, to balancing clinical, logistical, and personal factors to maximize quality of life.
-
Erin Neil Knierbein1moMaintaining independence in self care, eating, going to school/work are good consequences.
-
Anjaneyulu Alapati1moI would like to continue treatment until the pt completely looses motor strength. still breathing and swallowing is very important for me. of course finally pt and families decision also very important
-
Jorge Osorio1moThis a difficult , devastating disease for the patient and caregivers, we need all the tools can have in the treatment and improving quality of life.
-
Paola Sandroni1moPatients are typically quite realistic when they realize that is time to quit. I think now with the new drug coming out that opens a new avenue for particularly older patient that are not candidate for Zolgensma. I think we will have a new generation of patient that will coming to adulthood and we're totally changing the natural history of this condition and patient will need to have an SMN1 options 1st and then and SMN 2 moving forward.